NZNanshan Zhong

Nanshan Zhong

First Affiliated Hospital of Guangzhou Medical University
*This is an algorithmically generated author record based on publicly available information.
See Latest Publications
See Most Cited Publications
SciProfiles
ORCID Profile
Google Scholar

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Nanshan Zhong has a total of 14 co-authors. Here are the top co-authors by number of shared publications:

  • Chengzhi Zhou

    The First Affiliated Hospital of Guangzhou Medical University, National Center for Respiratory Medicine, National Clinical Research Center for Respiratory Disease, State Key Laboratory of Respiratory Disease, Guangzhou Institute of Respiratory Health, Guangzhou, 510000, PR China

    1 shared publication
  • Chengzhi Zhou

    State Key Laboratory of Respiratory Disease, National Clinical Research Center for Respiratory Disease, National Center for Respiratory Medicine, Department of Pulmonary and Critical Care Medicine, Guangzhou Institute of Respiratory Health, The First Affiliated Hospital of Guangzhou Medical University, Guangzhou, China

    1 shared publication
  • Gang Yang

    1 shared publication
  • Heng Lu

    1 shared publication
  • Lian Sheng Liu

    School of Biomedical Engineering, Guangzhou National Laboratory, Guangzhou Medical University, Guangzhou, Guangdong, 511436, China; Guangzhou National Laboratory, Guangzhou, Guangdong, 510000, China

    1 shared publication

  • Shiyue Li

    The First Affiliated Hospital of Guangzhou Medical University, National Center for Respiratory Medicine, National Clinical Research Center for Respiratory Disease, State Key Laboratory of Respiratory Disease, Guangzhou Institute of Respiratory Health, Guangzhou, 510000, PR China

    1 shared publication

Latest Publications

  • Website
    Google Scholar
    Open Access

    Oncology-respirology: a discipline in dire need

    by Chengzhi Zhou, Tao Luan, Weijie Guan, Wenhua Jian, Shuaiying Wang, Shiyue Li, Nanshan Zhong

    Cited by 8
  • Website
    Google Scholar
    Open Access

    First Case Report of Sunvozertinib for the Treatment of Her2 Exon 20 Insertion in Lung Adenocarcinoma

    by Tao Luan, Xin Qing Lin, Xiao Hong Xie, Shuai Yin Wang, Heng Lu, Lian Sheng Liu, Gang Yang, Yun Hui Zhang, Cheng Zhi Zhou

    Human Epidermal Growth Factor Receptor 2(HER2) is a transmembrane glycoprotein receptor with intracellular tyrosine kinase activity. It is generally considered as a poor prognostic marker. Targeted therapies, such as small molecule tyrosine kinase inhibitors (TKIs), showed limited efficacy in HER2-mutant advanced Non-Small Cell Lung Cancer (NSCLC). In the 2023 NCCN guidelines for NSCLC, Antibody-Drug Conjugate(ADC) Trastuzumab emtansine (T-DM1) is recommended for the treatment of HER2-mutant Lung Cancer (LC). However, this medication is currently not approved in certain regions.So it is necessary to explore alternative treatment options for HER2-mutant NSCLC patients.In our study of a patient with HER2 exon 20ins Lung Adenocarcinoma who had previously failed multiple TKI treatments, we discovered that Sunvozertinib could stabilize the patient's condition, achieving a progression-free survival (PFS) of 87 days. This is a novel finding that may provide new treatment options for HER2 exon 20ins patients who have failed TKI therapy.